Lionel Larue and his team are boosting our understanding of the PTEN gene’s role in melanoma, a very aggressive form of skin cancer. Mutations resulting in the loss of PTEN expression are commonly found in many forms of cancer and are associated with metastasis. However, we still know little about how these mutations occur within the cell.
MRV Research
Lion Biotechnologies Opens Enrollment in Phase 2 Study of LN-144 for the Treatment of Refractory Metastatic Melanoma
Lion Biotechnologies, Inc. (Nasdaq:LBIO) a biotechnology company that is developing novel cancer immunotherapies based on tumor-infiltrating lymphocytes (TIL), today announced that it has opened enrollment in a Phase 2 clinical trial of its lead product candidate, LN-144, for the treatment of refractory metastatic melanoma.
Trametinib: A MEK inhibitor for management of metastatic melanoma
Trametinib (Mekinst), a novel oral kinase inhibitor, is indicated as a single agent and in combination with dabrafenib (Tafinlar) for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutation. It is not intended for monotherapy in patients who have received prior BRAF-inhibitor therapy.
UCLA researchers’ discovery is milestone in understanding treatment-resistant melanoma
Within the past few years, new treatments have begun to turn the tide against metastatic melanoma, improving and even saving the lives of countless people with this deadly disease.